Cover Image

A Unique Case Report of Hypertrophic Osteoarthropathy Associated With Endometrial Cancer and Literature Review.

Yolanda Pina, Sowmya Nanjappa, Ebone'D Hill


Introduction:  In this manuscript, we present an oncological case of hypertrophic osteoarthropathy (HOA) associated with endometrial cancer.

Presentation of the case:  A 46 year-old woman with a history of endometrial cancer (ER+/PR+) presented with hemoptysis and severe diffuse muscle and joint pain, intractable to hydromorphone and non-steroidal-anti-inflammatories. She was diffusely tender to palpation, prominently in the bilateral lower extremities. Bone scintigraphy showed diffuse osteoblastic activity in all extremities, most prominent in the tibiae, concordant with HOA.  Patient was treated with zoledronic acid (ZA) and ketorolac, achieving adequate pain control. 

Conclusion:  HOA has been associated with multiple primary malignancies, as well as other medical conditions.  Its association with endometrial cancer has been rarely described in the literature.  The pathophysiology of this disorder is poorly understood.  More studies are needed to further enhance our understanding of this rare disease.


Hypertrophic; osteoarthropathy; endometrial cancer; malignancy; pain control; zoledronic acid


Silveira LH, Martinez-Lavin M, Pineda C, Fonseca MC, Navarro C, Nava A. Vascular endothelial growth factor and hypertrophic osteoarthropathy. Clinical and experimental rheumatology. 2000, 18:57-62

Sonthalia N, Mukherjee K, Saha A, Talukdar A. Treatment of hypertrophic osteoarthropathy in the case of pulmonary metastasis secondary-to-nasopharyngeal carcinoma with zoledronic acid: An enlightening experience. BMJ case reports. 2012, 2012

Castori M, Sinibaldi L, Mingarelli R, Lachman RS, Rimoin DL, Dallapiccola B. Pachydermoperiostosis: An update. Clin Genet. 2005, 68:477-486

Zhang Z, Zhang C, Zhang Z. Primary hypertrophic osteoarthropathy: An update. Frontiers of medicine. 2013, 7:60-64

Martinez-Lavin M, Matucci-Cerinic M, Jajic I, Pineda C. Hypertrophic osteoarthropathy: Consensus on its definition, classification, assessment and diagnostic criteria. The Journal of rheumatology. 1993, 20:1386-1387

Shih WJ. Pulmonary hypertrophic osteoarthropathy and its resolution. Seminars in nuclear medicine. 2004, 34:159-163

Yao Q, Altman RD, Brahn E. Periostitis and hypertrophic pulmonary osteoarthropathy: Report of 2 cases and review of the literature. Seminars in arthritis and rheumatism. 2009, 38:458-466

Yeo W, Leung SF, Chan AT, Chiu KW. Radiotherapy for extreme hypertrophic pulmonary osteoarthropathy associated with malignancy. Clin Oncol (R Coll Radiol). 1996, 8:195-197

Morita M, Sakaguchi Y, Kuma S, Kajiyama K, Sugio K, Yasumoto K. Hypertrophic osteoarthropathy associated with esophageal cancer. The Annals of thoracic surgery. 2003, 76:1744-1746

Pallecaros A, Ross BA, Gates L, Webb FW. Oesophago-gastrectomy for marie-bamberger syndrome. Journal of the Royal Society of Medicine. 1992, 85:635-636

Ullal SR. Hypertrophic osteoarthropathy and leiomyoma of the esophagus. Am J Surg. 1972, 123:356-358

Collier DH, Zulman JI. Hypertrophic osteoarthropathy associated with achalasia. Am J Med. 1986, 81:355-360

Suzuma T, Sakurai T, Yoshimura G, Umemura T, Tamaki T, Yoshimasu T, Naito Y. Pamidronate-induced remission of pain associated with hypertrophic pulmonary osteoarthropathy in chemoendocrine therapy-refractory inoperable metastatic breast carcinoma. Anticancer Drugs. 2001, 12:731-734

Atkinson MK, McElwain TJ, Peckham MJ, Thomas PP. Hypertrophic pulmonary osteoarthropathy in hodgkin's disease: Reversal with chemotherapy. Cancer. 1976, 38:1729-1734

Frand M, Koren G, Rubinstein Z. Reversible hypertrophic osteoarthropathy associated with cyanotic congenital heart disease. Am J Dis Child. 1982, 136:687-689

Dickinson CJ, Martin JF. Megakaryocytes and platelet clumps as the cause of finger clubbing. Lancet. 1987, 2:1434-1435

Letts M, Pang E, Simons J. Prostaglandin-induced neonatal periostitis. J Pediatr Orthop. 1994, 14:809-813

Katsicas M, Ciocca M, Rosanova M, Russo R. Hypertrophic osteoarthropathy in two children with cholestatic hepatic disease. Acta paediatrica. 2005, 94:1152-1155

Taillandier J, Alemanni M, Samuel D, Bismuth H. Hepatic hypertrophic osteoarthropathy: The value of liver transplantation. Clinical and experimental rheumatology. 1998, 16:80-81

Huaux JP, Geubel A, Maldague B, Michielsen P, de Hemptinne B, Otte JB, de Deuxchaisnes CN. Hypertrophic osteoarthropathy related to end stage cholestatic cirrhosis: Reversal after liver transplantation. Annals of the rheumatic diseases. 1987, 46:342-345

Pitt P, Mowat A, Williams R, Hamilton E. Hepatic hypertrophic osteoarthropathy and liver transplantation. Annals of the rheumatic diseases. 1994, 53:338-340

Ntaios G, Adamidou A, Karamitsos D. Hypertrophic pulmonary osteoarthropathy secondary to bronchial adenocarcinoma and coexisting pulmonary tuberculosis: A case report. Cases journal. 2008, 1:221

Alonso-Bartolome P, Martinez-Taboada VM, Pina T, Blanco R, Rodriguez-Valverde V. Hypertrophic osteoarthropathy secondary to vascular prosthesis infection: Report of 3 cases and review of the literature. Medicine. 2006, 85:183-191

Amital H, Applbaum YH, Vasiliev L, Rubinow A. Hypertrophic pulmonary osteoarthropathy: Control of pain and symptoms with pamidronate. Clinical rheumatology. 2004, 23:330-332

Garske LA, Bell SC. Pamidronate results in symptom control of hypertrophic pulmonary osteoarthropathy in cystic fibrosis. Chest. 2002, 121:1363-1364

Augarten A, Goldman R, Laufer J, Szeinberg A, Efrati O, Barak A, Miller MS, Yahav Y. Reversal of digital clubbing after lung transplantation in cystic fibrosis patients: A clue to the pathogenesis of clubbing. Pediatr Pulmonol. 2002, 34:378-380

Margolick J, Bonomi P, Fordham E, Yordan E, Slayton R, Wilbanks G. Hypertrophic osteoarthropathy associated with endometrial carcinoma. Gynecologic oncology. 1982, 13:399-404

Yacoub MH, Simon G, Ohnsorge J. Hypertrophic pulmonary osteoarthropathy in association with pulmonary metastases from extrathoracic tumours. Thorax. 1967, 22:226-231

Heldin CH, Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev. 1999, 79:1283-1316

Silveri F, De Angelis R, Argentati F, Brecciaroli D, Muti S, Cervini C. Hypertrophic osteoarthropathy: Endothelium and platelet function. Clinical rheumatology. 1996, 15:435-439

Kawai T, Hiroi S, Torikata C. Expression in lung carcinomas of platelet-derived growth factor and its receptors. Lab Invest. 1997, 77:431-436

Landrum ML, Ornstein DL. Hypertrophic osteoarthropathy associated with metastatic phyllodes tumor. American journal of clinical oncology. 2003, 26:146-150

Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: A critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2002, 20:4368-4380

Pina Y, Houston SK, Murray TG, Koru-Sengul T, Decatur C, Scott WK, Nathanson L, Clarke J, Lampidis TJ. Retinoblastoma treatment: Impact of the glycolytic inhibitor 2-deoxy-d-glucose on molecular genomics expression in lh(beta)t(ag) retinal tumors. Clin Ophthalmol. 2012, 6:817-830

Pina Y, Boutrid H, Schefler A, Dubovy S, Feuer W, Jockovich ME, Murray TG. Blood vessel maturation in retinoblastoma tumors: Spatial distribution of neovessels and mature vessels and its impact on ocular treatment. Invest Ophthalmol Vis Sci. 2009, 50:1020-1024

Ferrara N. Vascular endothelial growth factor: Basic science and clinical progress. Endocr Rev. 2004, 25:581-611

Nguyen S, Hojjati M. Review of current therapies for secondary hypertrophic pulmonary osteoarthropathy. Clinical rheumatology. 2011, 30:7-13

Saenz RE, Sears BW, Dabisch PA. Hardcore pharmacology. 2006, Chapter 7: Endocrine Pharmacology:71-82

King MM, Nelson DA. Hypertrophic osteoarthropathy effectively treated with zoledronic acid. Clinical lung cancer. 2008, 9:179-182

Speden D, Nicklason F, Francis H, Ward J. The use of pamidronate in hypertrophic pulmonary osteoarthropathy (hpoa). Aust N Z J Med. 1997, 27:307-310

Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, Apffelstaedt J, Hussein M, Coleman RE, Reitsma DJ, Seaman JJ, Chen BL, Ambros Y. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: A phase iii, double-blind, comparative trial. Cancer J. 2001, 7:377-387

Lipton A, Small E, Saad F, Gleason D, Gordon D, Smith M, Rosen L, Kowalski MO, Reitsma D, Seaman J. The new bisphosphonate, zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: A comparison to pamidronate. Cancer Invest. 2002, 20 Suppl 2:45-54

Wood J, Bonjean K, Ruetz S, Bellahcene A, Devy L, Foidart JM, Castronovo V, Green JR. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther. 2002, 302:1055-1061

Kimmel DB. Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates. J Dent Res. 2007, 86:1022-1033

Qiu L, Lv G, Cao Y, Chen L, Yang H, Luo S, Zou M, Lin J. Synthesis and biological evaluation of novel platinum complexes of imidazolyl-containing bisphosphonates as potential anticancer agents. J Biol Inorg Chem. 2015, 20:1263-1275

Khandelwal VK, Mitrofan LM, Hyttinen JM, Chaudhari KR, Buccione R, Kaarniranta K, Ravingerova T, Monkkonen J. Oxidative stress plays an important role in zoledronic acid-induced autophagy. Physiol Res. 2014, 63 Suppl 4:S601-612

Liu SS, Wang XP, Li XB, Liang JY, Liu LL, Lu Y, Zhong XY, Chen YX. Zoledronic acid exerts antitumor effects in nb4 acute promyelocytic leukemia cells by inducing apoptosis and s phase arrest. Biomed Pharmacother. 2014, 68:1031-1036

Insalaco L, Di Gaudio F, Terrasi M, Amodeo V, Caruso S, Corsini LR, Fanale D, Margarese N, Santini D, Bazan V, Russo A. Analysis of molecular mechanisms and anti-tumoural effects of zoledronic acid in breast cancer cells. J Cell Mol Med. 2012, 16:2186-2195

Blackwell N, Bangham L, Hughes M, Melzack D, Trotman I. Treatment of resistant pain in hypertrophic pulmonary arthropathy with ketorolac. Thorax. 1993, 48:401

Leung FW, Williams AJ, Fan P. Indomethacin therapy for hypertrophic pulmonary osteoarthropathy in patients with bronchogenic carcinoma. West J Med. 1985, 142:345-347

Matzinger MA, Briggs VA, Dunlap HJ, Udjus K, Martin DJ, McDonald P. Plain film and ct observations in prostaglandin-induced bone changes. Pediatric radiology. 1992, 22:264-266

Wulfeck DW, Williams TE, Eberly S. Scintigraphic diagnosis of prostaglandin induced periostitis. Clinical nuclear medicine. 1995, 20:282

Ringel RE, Brenner JI, Haney PJ, Burns JE, Moulton AL, Berman MA. Prostaglandin-induced periostitis: A complication of long-term pge1 infusion in an infant with congenital heart disease. Radiology. 1982, 142:657-658

Kozak KR, Milne GL, Morrow JD, Cuiffo BP. Hypertrophic osteoarthropathy pathogenesis: A case highlighting the potential role for cyclo-oxygenase-2-derived prostaglandin e2. Nature clinical practice. Rheumatology. 2006, 2:452-456

Full Text: PDF


  • There are currently no refbacks.

AJCC-REP (ISSN 2572-5742)Copyright © 2012-2017. All rights reserved. Published by Ivy Union Publishing, 3204 Valley Rush Dr, Apex, North Carolina 27502, United States